RetroSense develops gene therapies designed to restore functional vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration (AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these degenerative conditions. RetroSense strives to provide the solution to this growing need.